NCT00566696 · OUTCOME

Incidence of Regimen-related Mortality

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies · Source last updated 2020-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: Not reported
Time frame: 100 days post-transplant

What was measured

The incidence of regimen-related mortality in the first 100 days post-transplant is estimated based on binomial distribution.

Groups in this outcome

High-Risk Hematologic Malignancies

Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
High-Risk Hematologic Malignancies	31

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
High-Risk Hematologic Malignancies	9.68	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
9.68

denoms

counts
group Id
OG000
value
31
units
Participants

description

The incidence of regimen-related mortality in the first 100 days post-transplant is estimated based on binomial distribution.

groups

description
Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.
id
OG000
title
High-Risk Hematologic Malignancies

param Type

NUMBER

reporting Status

POSTED

time Frame

100 days post-transplant

title

Incidence of Regimen-related Mortality

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice